Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
2 drugs for “Metastatic Urothelial Carcinoma”
Phase 3 1
- IvonescimabSummit Therapeutics Inc.Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma (UC) · next catalyst 14 Nov 2026
Phase 2/3 1
- Ivonescimab RP3DSummit Therapeutics Inc.Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma (UC)
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.